Exact Sciences stock holds strong gains after recent rally

Published on 09/09/2026 at 11:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Exact Sciences stock has climbed sharply over the past 12 months, with a 90.9% price gain as of September 9, 2026. The move follows solid recent results and guidance that keep the diagnostics specialist in focus for growth-oriented investors.

Wissenschaftlerinnen analysieren Krebsproben in einem modernen Diagnostiklabor von Exact Sciences — Exact Sciences Corp. betreibt hochmoderne Labore für die molekulare Krebsfrüherkennung weltweit ISIN US30063P1057, Illustration mit AI erstellt.

Exact Sciences stock (ISIN US30063P1057) has delivered a powerful performance, with the shares up 90.9% over the past 12 months and trading around USD 104.91 as of September 9, 2026 according to comparative data for EXAS.

Strong price performance sets the tone

As of September 9, 2026, a stock comparison overview shows Exact Sciences at a price of about USD 104.91 per share, representing a 12-month change of plus 90.9 percent, underlining how strongly the stock has appreciated over the past year compared with peers.AltIndex

This performance signal means that, historically, an investor who bought Exact Sciences stock roughly a year earlier would now be sitting on a near-doubling of the investment, a stark contrast to the negative market capitalization development of the comparison company highlighted in the same overview.AltIndex

Recent fundamentals underpin the valuation

In addition to the strong price performance, Exact Sciences has reported growing revenue and improved operating metrics in its most recent quarters, giving fundamental backing to the move in the stock. According to recent company and portal summaries of the latest interim report for fiscal 2026, quarterly revenue for Exact Sciences increased compared with the prior-year period, and the company continued to invest in its core cancer diagnostics platforms while managing margins within guidance ranges.Exact Sciences

Across the latest reported quarter in 2026, total revenue rose at a double-digit rate versus the prior-year quarter, with core screening and precision oncology segments contributing to the advance. Historical comparisons show that, in fiscal year 2024, revenue already stood at a significantly higher level than in 2023, and the more recent quarterly figures now build on that base as the company scales its test volumes and partnerships.Exact Sciences

Management has reiterated guidance ranges for the current year in its latest communication, signaling confidence that revenue and adjusted EBITDA can continue to grow in line with earlier outlooks. For investors, this combination of consistent guidance and realized growth in the most recent interim period is a key reason why the valuation multiple on Exact Sciences stock remains elevated compared with more mature peers in the diagnostics and life sciences sector.Exact Sciences

Analyst view and risk factors

Analyst coverage over recent months has generally emphasized Exact Sciences as a growth story in cancer diagnostics, with price targets that factor in continued expansion of screening volumes and new test launches. Where data are available, brokerage notes frequently highlight upside scenarios based on stronger-than-expected adoption of the company’s flagship colorectal cancer test and emerging products, while also pointing to risks such as reimbursement changes, competitive pressure from other diagnostics players and the need for ongoing investment in clinical evidence.

The sharp 90.9 percent share price gain over 12 months means that any earnings or guidance disappointment in coming quarters could translate into pronounced volatility in Exact Sciences stock, particularly if revenue growth slows versus the double-digit trends seen in the latest reporting period.AltIndex For investors, the balance between continued execution on growth initiatives and the valuation implied by the recent rally is therefore central when assessing the stock.

Stock level and investor takeaway

With Exact Sciences stock around USD 104.91 as of September 9, 2026, and a 12-month gain of 90.9 percent from the level a year earlier, the shares are currently trading close to the upper end of their historical range over that period, supported by improving fundamentals and sustained growth expectations.AltIndex